Overview

* Penumbra Q3 revenue grows 17.8% yr/yr, beating analyst expectations

* Net income for Q3 was $45.9 mln, reflecting improved operational performance

* Company's U.S. thrombectomy revenue grows 18.5%, driven by product sales

Outlook

* Company raises 2025 revenue guidance to $1.375 bln to $1.380 bln

* Company maintains U.S. Thrombectomy growth guidance at 20% to 21%

* Penumbra keeps full-year gross and operating margin guidance unchanged

Result Drivers

* U.S. THROMBECTOMY SALES - U.S. thrombectomy revenue grew 18.5% driven by product sales

* EMBOLIZATION PRODUCT GROWTH - U.S. embolization and access products increased by 29.2%

* GROSS MARGIN IMPROVEMENT - Gross margin improved due to favorable product mix and productivity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $354.69 $340.80

Revenue mln mln (18

Analysts

)

Q3 Net $45.85

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Penumbra Inc ( PEN ) is $320.00, about 26.5% above its November 4 closing price of $235.08

* The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 56 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)